Home › Funds › Prosight Management, LP › ANTX
Prosight Management, LP position in ANTX
AN2 THERAPEUTICS INC · Health Care
Prosight Management, LP reported holding 350,877 shares of ANTX (AN2 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.36% of its reported portfolio and ranking #25 among its reported holdings. Prosight Management, LP has disclosed ANTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's ANTX position evolved
Prosight Management, LP first disclosed a stake in ANTX in Q1 2026 at 515,754 shares (US$1.8M). The position peaked in Q2 2026 at 474,638 shares, worth US$2.3M. Across 3 filings, Prosight Management, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 350,877 shares valued at US$1.9M — a reduction of -123,761 shares quarter over quarter.. Notable position changes include a 26% trim in Q3 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 515.75K | $1.76M | New |
| Q2 2026 | 474.64K | $2.30M | Reduce |
| Q3 2026 | 350.88K | $1.87M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANTX and 13F data
ANTX (AN2 THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ANTX — the largest reported positions include Vivo Capital, LLC (US$16.8M), Commodore Capital LP (US$14.2M), Spruce Street Capital LP (US$9.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANTX
- Vivo Capital, LLC 3.15M sh · $16.78M · Q3 2026
- Commodore Capital LP 2.93M sh · $14.20M · Q2 2026
- Spruce Street Capital LP 1.75M sh · $9.32M · Q3 2026
- Almitas Capital LLC 1.47M sh · $7.11M · Q2 2026
- Boxer Capital Management, LLC 749.03K sh · $3.63M · Q2 2026
- Sio Capital Management, LLC 529.93K sh · $2.56M · Q2 2026
- Ally Bridge Group (NY) LLC 526.32K sh · $2.55M · Q2 2026
- Aldebaran Capital, LLC 367.71K sh · $1.96M · Q3 2026
- Stonepine Capital Management, LLC 350.88K sh · $1.87M · Q3 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held ANTX?
Prosight Management, LP has disclosed ANTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Prosight Management, LP's current position in ANTX?
As of Q3 2026, Prosight Management, LP holds 350.88K shares of ANTX (AN2 THERAPEUTICS INC), valued at $1.87M, representing 0.36% of its reported portfolio and ranking #25.
Has Prosight Management, LP been buying or selling ANTX?
In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in ANTX. The position peaked in Q2 2026 at 474.64K shares.
Which other funds hold ANTX?
Other major institutional holders of ANTX include Vivo Capital, LLC, Commodore Capital LP, Spruce Street Capital LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.